BR112017028604A2 - forma cristalina de base livre de lorlatinibe - Google Patents

forma cristalina de base livre de lorlatinibe

Info

Publication number
BR112017028604A2
BR112017028604A2 BR112017028604A BR112017028604A BR112017028604A2 BR 112017028604 A2 BR112017028604 A2 BR 112017028604A2 BR 112017028604 A BR112017028604 A BR 112017028604A BR 112017028604 A BR112017028604 A BR 112017028604A BR 112017028604 A2 BR112017028604 A2 BR 112017028604A2
Authority
BR
Brazil
Prior art keywords
free base
crystalline form
base crystalline
lorlatinib free
lorlatinib
Prior art date
Application number
BR112017028604A
Other languages
English (en)
Portuguese (pt)
Inventor
Dimitrova Pencheva Klimentina
J Birch Melissa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56686850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017028604(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR112017028604A2 publication Critical patent/BR112017028604A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112017028604A 2015-07-31 2016-07-27 forma cristalina de base livre de lorlatinibe BR112017028604A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199418P 2015-07-31 2015-07-31
US201662352349P 2016-06-20 2016-06-20
PCT/IB2016/054483 WO2017021823A1 (en) 2015-07-31 2016-07-27 Crystalline form of lorlatinib free base

Publications (1)

Publication Number Publication Date
BR112017028604A2 true BR112017028604A2 (pt) 2018-09-04

Family

ID=56686850

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028604A BR112017028604A2 (pt) 2015-07-31 2016-07-27 forma cristalina de base livre de lorlatinibe

Country Status (22)

Country Link
US (2) US10420749B2 (cg-RX-API-DMAC7.html)
EP (2) EP3328867B9 (cg-RX-API-DMAC7.html)
JP (1) JP6218253B2 (cg-RX-API-DMAC7.html)
KR (1) KR102088188B1 (cg-RX-API-DMAC7.html)
CN (3) CN107849060A (cg-RX-API-DMAC7.html)
AU (1) AU2016304420B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017028604A2 (cg-RX-API-DMAC7.html)
CA (1) CA2937257C (cg-RX-API-DMAC7.html)
CY (1) CY1123689T1 (cg-RX-API-DMAC7.html)
DK (2) DK3328867T3 (cg-RX-API-DMAC7.html)
ES (2) ES2842302T3 (cg-RX-API-DMAC7.html)
FI (1) FI3798222T3 (cg-RX-API-DMAC7.html)
HK (1) HK1252845A1 (cg-RX-API-DMAC7.html)
HU (2) HUE065536T2 (cg-RX-API-DMAC7.html)
MX (2) MX395263B (cg-RX-API-DMAC7.html)
PL (2) PL3328867T3 (cg-RX-API-DMAC7.html)
PT (2) PT3798222T (cg-RX-API-DMAC7.html)
RU (1) RU2018101363A (cg-RX-API-DMAC7.html)
SG (1) SG10201913200XA (cg-RX-API-DMAC7.html)
SI (2) SI3798222T1 (cg-RX-API-DMAC7.html)
TW (1) TWI616449B (cg-RX-API-DMAC7.html)
WO (1) WO2017021823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998885C (en) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
CA3019905C (en) 2016-04-08 2022-08-23 Pfizer Inc. Crystalline forms of lorlatinib maleate
WO2018232506A1 (en) * 2017-06-22 2018-12-27 Cyclenium Pharma Inc. MACROCYCLIC COMPOUND LIBRARIES CONTAINING PYRIDINE AND METHODS FOR PREPARING AND USING SAME
SI3694863T1 (sl) * 2017-10-10 2023-10-30 Pfizer Inc. Kristalna oblika hidrata proste baze lorlatiniba
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019209633A1 (en) 2018-04-23 2019-10-31 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN113260617A (zh) * 2019-01-17 2021-08-13 辉瑞公司 Cdk抑制剂的结晶形式
US12391708B2 (en) 2019-07-18 2025-08-19 Tapi Croatia Industries Ltd Crystalline Lorlatinib : fumaric acid and solid state form thereof
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
CN110530998A (zh) * 2019-09-16 2019-12-03 山东省药学科学院 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法
EP4041396A1 (en) 2019-10-10 2022-08-17 Sandoz AG Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796967C (en) 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CA2916605C (en) 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CA3019905C (en) 2016-04-08 2022-08-23 Pfizer Inc. Crystalline forms of lorlatinib maleate
SI3694863T1 (sl) 2017-10-10 2023-10-30 Pfizer Inc. Kristalna oblika hidrata proste baze lorlatiniba

Also Published As

Publication number Publication date
MX395263B (es) 2025-03-25
US20180235933A1 (en) 2018-08-23
SG10201913200XA (en) 2020-03-30
NZ739304A (en) 2024-11-29
MX382600B (es) 2025-03-13
CN116063323B (zh) 2026-06-30
PT3798222T (pt) 2024-01-22
EP3798222A1 (en) 2021-03-31
CA2937257A1 (en) 2017-01-31
CN116063322A (zh) 2023-05-05
US10420749B2 (en) 2019-09-24
DK3798222T3 (da) 2023-12-11
JP2017039702A (ja) 2017-02-23
WO2017021823A1 (en) 2017-02-09
HUE065536T2 (hu) 2024-05-28
AU2016304420B2 (en) 2019-09-19
CY1123689T1 (el) 2022-03-24
EP3328867B9 (en) 2021-04-14
PT3328867T (pt) 2021-01-13
PL3798222T3 (pl) 2024-03-25
PL3328867T3 (pl) 2021-04-19
TWI616449B (zh) 2018-03-01
JP6218253B2 (ja) 2017-10-25
RU2018101363A (ru) 2019-08-29
RU2018101363A3 (cg-RX-API-DMAC7.html) 2019-08-29
MX2018001324A (es) 2018-04-30
HK1252845A1 (zh) 2019-06-06
MX2021002220A (es) 2022-09-01
KR102088188B1 (ko) 2020-03-12
EP3328867B1 (en) 2020-11-11
EP3328867A1 (en) 2018-06-06
HUE052790T2 (hu) 2021-05-28
FI3798222T3 (fi) 2023-11-28
DK3328867T3 (da) 2020-11-16
KR20180022936A (ko) 2018-03-06
SI3328867T1 (sl) 2021-04-30
SI3798222T1 (sl) 2024-02-29
TW201718600A (zh) 2017-06-01
CN107849060A (zh) 2018-03-27
ES2972010T3 (es) 2024-06-10
US20190365712A1 (en) 2019-12-05
EP3798222B1 (en) 2023-11-22
AU2016304420A1 (en) 2018-02-01
CA2937257C (en) 2022-06-14
ES2842302T3 (es) 2021-07-13
US11020376B2 (en) 2021-06-01
CN116063323A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
DOP2019000030A (es) Inhibidores de cdk2/4/6
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
CO2017003011A2 (es) Derivados de benzodiazepina citotóxicos
MX2017000450A (es) Compuestos terapeuticos inhibidores.
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
MX2021001441A (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PE20170193A1 (es) Derivados de 6-alquinil-piridina
PY1515461A (es) Derivados de Dihidropirrolopirimidina
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
BR112017009503A2 (pt) composição farmacêutica parenteral de ação prolongada, métodos para tratar, para prevenir e para curar uma infecção por hcv, e, kit.
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
NZ778505A (en) Crystalline form of lorlatinib free base
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]